Vaccination and treatment trials against murine leishmaniasis with semi-purified Leishmania antigens.
Antigens with molecular weight ranges of 94-67 kDa (LiF2), 30-20 kDa (LiF5), or below 20 kDa (LiF6), isolated from lysates of Leishmania infantum promastigotes by electroelution from polyacrylamide gels were injected into mice which were genetically either partially resistant (C57BL/6) or susceptible (BALB/c) to Leishmania infection. One month after the completion of the intravenous (C57BL/6) or subcutaneous (BALB/c) schedules, the mice were challenged with 1 x 10(3) L. major promastigotes. All mice immunized with LiF2, LiF5 and LiF6 were completely resistant. Furthermore, the C57BL/6 mice immunized with LiF2 resisted a second challenge with 1 x 10(4) L. major amastigotes. 5 months later, LiF2 antigen was used for immunotherapy of L. major leishmaniasis; parasites disappeared from the treated skin lesions, although ensuing systemic infection could not be averted.
Monjour
L
L
Laboratoire de Parasitologie Expérimentale, CHU Pitié-Salpétrière, Paris, France.
Vouldoukis
I
I
Ogunkolade
B W
BW
Hetzel
C
C
Ichen
M
M
Frommel
D
D
D000818:Animals; D000953:Antigens, Protozoan / Q000008:administration & dosage*; D005260:Female; D007114:Immunization; D007167:Immunotherapy; D007893:Leishmania donovani / Q000276:immunology*; D007898:Leishmaniasis, Visceral / Q000517:prevention & control* / Q000628:therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL
D000953:Antigens, Protozoan